RxDoctor Payments Data

Beverly Tchang, MD

Endocrinology, Diabetes & Metabolism · New York, NYNPI 1194067587

Payments from drug & device makers

$120,398in general payments, 2019–2025

Across 135 payments — averaging $891.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$73K
  • Boehringer Ingelheim$20K
  • Eli Lilly$16K
  • Amgen$5K
  • F. Hoffmann-la Roche AG$3K
  • Madrigal Pharmaceuticals$2K
  • plus $2K from 8 others

What the payments were for

  • Consulting fees$98,12882%
  • Travel & lodging$17,00014%
  • Food & beverage$5,2704%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,398 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York

Medicare billing

Part B allowed, 2024
$46,719
Medicare patients
128
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$255,948
MounjaroTirzepatide110$146,116
JardianceEmpagliflozin38$42,775
TrulicityDulaglutide22$33,740
RybelsusSemaglutide22$28,600
Metformin Hcl ErMetformin Hcl207$3,305
Nano 2nd Gen Pen NeedlePen Needle, Diabetic27$2,081
Liothyronine Sodium38$1,497
SynthroidLevothyroxine Sodium18$1,466
Topiramate66$1,377
Bupropion XlBupropion Hcl24$1,178
Naltrexone Hcl11$1,119
Levothyroxine Sodium64$1,052
Bupropion Hcl SrBupropion Hcl25$503
Rosuvastatin Calcium12$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$72,632$284,549137 claims
Lilly USA, LLCMounjaro, Trulicity$285$179,856132 claims
Boehringer IngelheimJardiance$20,226$42,77538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →